GO
Loading...

Enter multiple symbols separated by commas

Stocks Merck & Co Inc

More

  • Investors on Fed statement, first-quarter GDP watch Wednesday, 29 Apr 2015 | 6:00 AM ET
    The Federal Reserve building in Washington.

    Investors will scrutinize US growth as the initial read on the first-quarter GDP comes ahead of a meeting statement from a 'data-dependent' Fed.

  • Asian equities retreat on lackluster earnings; Fed eyed Wednesday, 29 Apr 2015 | 3:30 AM ET

    Asian markets mostly fell on Wednesday as investors digested the raft of earnings due in the region and awaited the Federal Reserve's statement.

  • Investors on Fed watch as statement, GDP come out Tuesday, 28 Apr 2015 | 6:56 PM ET
    The Federal Reserve building in Washington.

    Investors will scrutinize US growth as the initial read on the first-quarter GDP comes ahead of a meeting statement from a 'data-dependent' Fed.

  • Traders work on the floor of the New York Stock Exchange.

    U.S.stocks closed mixed on Tuesday as investors eyed tech earnings and awaited the Federal Reserve's statement on Wednesday.

  • Dollar hits Pfizer; Merck 'blew away' estimates Tuesday, 28 Apr 2015 | 9:04 AM ET
    Tablets of Pfizer Inc.'s Lipitor and Merck & Co.'s Zocor.

    Pfizer reported a 4 percent drop in quarterly revenue, while Merck posted earnings that topped expectations.

  • Janet Yellen

    U.S. stock index futures indicated a flat open on Tuesday ahead of the two-day FOMC meeting, housing data and a busy day of earnings.

  • April 28- Merck& Co's shares jumped almost 5 percent after the U.S. drugmaker reported better-than-expected quarterly results and released favorable data late Monday about the safety of its Januvia diabetes drug. The second-largest U.S. drugmaker on Tuesday said it earned $953 million, or 33 cents per share, in the first quarter. That compared with $1.71...

  • Innovation driving big pharma: Pro Tuesday, 28 Apr 2015 | 8:09 AM ET
    Innovation driving big pharma: Pro

    Seamus Fernandez, Leerink Partners, and Barbara Ryan, Clermont Partners, share their thoughts on what's driving big pharma profits.

  • Merck 'blew away the quarter': Pro Tuesday, 28 Apr 2015 | 8:05 AM ET
    Merck 'blew away the quarter': Pro

    Seamus Fernandez, Leerink Partners, and Barbara Ryan, Clermont Partners, break down the numbers on Pfizer's "ok" quarter, and Merck's "spectacular" results.

  • Early movers: BP, F, AAPL, BMY, COH, PFE & more Tuesday, 28 Apr 2015 | 8:01 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • All eyes on Pfizer and Merck earnings Tuesday, 28 Apr 2015 | 5:30 AM ET
    All eyes on Pfizer and Merck earnings

    Ranjith Gopinathan, program manager of life sciences and healthcare practice at Frost & Sullivan, shares his forecasts for Pfizer and Merck earnings.

  • Health care, Tesla top Halftime's trades to go Monday, 27 Apr 2015 | 2:49 PM ET

    The "Halftime Report" traders give their trades for the second half.

  • *FDA cites concerns over late-stage study design, results. April 27- U.S. Food and Drug Administration staff reviewers said an accelerated review of drugmaker Amgen Inc's skin cancer immunotherapy cannot be considered at this time, citing concerns over the design and results of a key study. T-Vec represents a new class of agent for the treatment of metastatic...

  • Why the S&P could break out this week Monday, 27 Apr 2015 | 7:12 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • Bulls sniffing out an S&P breakout Monday, 27 Apr 2015 | 6:00 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • NEW YORK, April 24- Healthcare companies on a seven-year tear have been top performers so far in 2015, helping to push broad stock indexes to record levels, but traders are now looking to protect themselves from a selloff as they await major earnings reports in the sector. Companies reporting first-quarter earnings next week include Bristol-Meyers Squibb Co,...

  • LONDON, April 24- European regulators have recommended approval of Bristol-Myers Squibb's Opdivo, paving the way for it to become the first of a closely watched group of immune system-boosting cancer medicines to go on sale in Europe. It competes with Merck& Co's Keytruda, which is also on the market in the United States but not in Europe. Although Keytruda is...

  • April 23- A unit of AstraZeneca Plc has teamed up with Juno Therapeutics Inc to develop combination treatments that use the body's immune system to kill cancer cells. The partnership between AstraZeneca's research and development arm MedImmune and Juno is the latest collaboration between companies intent on developing a new class of drugs known as...

  • Tekmira Ebola drug succeeds in small monkey study Wednesday, 22 Apr 2015 | 1:00 PM ET

    NEW YORK, April 22- An experimental Ebola drug from Tekmira Pharmaceuticals Corp cured all three monkeys intentionally infected with the virus, scientists reported on Wednesday, the first such success against the strain of Ebola in West Africa's 2014-2015 outbreak. Although other experimental treatments appeared to help Ebola patients last year,...

  • April 17- A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their...